Rani Therapeutics CTO reports stock dispositions

Rani Therapeutics Holdings, Inc. Chief Technical Officer Alireza Javadi reported two dispositions of Class A Common Stock related to restricted stock unit settlements.

Rhea-AI Filing Summary

Rani Therapeutics Holdings, Inc. Chief Technical Officer Alireza Javadi reported two dispositions of Class A Common Stock related to restricted stock unit settlements. On March 27, 2026, he sold 386 shares at $0.78 per share to cover tax withholding obligations. On June 27, 2026, 309 shares at $0.74 per share were withheld and surrendered to the issuer to satisfy tax withholding obligations. Both transactions were reported late due to inadvertent administrative oversight.

Insider Trade Summary

Net Seller: 386 shares

Net Sell 2 txns

Insider Javadi Alireza

Role Chief Technical Officer

Sold 386 shs ($301.08)

Type	Security	Shares	Price	Value
Tax Withholding	Class A Common Stock F1, F3	309	$0.74	$228.66
Sale	Class A Common Stock F1, F2	386	$0.78	$301.08

Holdings After Transaction: Class A Common Stock — 9,380 shares (Direct)

Footnotes (3)

1. F1. This transaction is being reported late due to inadvertent administrative oversight.
2. F2. Represents the sale of shares to cover tax withholding obligations in connection with the settlement and release of the restricted stock units.
3. F3. Represents shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations in connection with the settlement and release of the restricted stock units.

Key Figures

Shares sold: 386 shares Sale price: $0.78 per share Shares withheld for taxes: 309 shares +1 more

4 metrics

Shares sold 386 shares Sale of Class A Common Stock on March 27, 2026 to cover tax withholding obligations

Sale price $0.78 per share Price for the 386 shares of Class A Common Stock sold on March 27, 2026

Shares withheld for taxes 309 shares Shares withheld and surrendered on June 27, 2026 to satisfy tax withholding obligations

Withholding price $0.74 per share Price attributed to the 309 shares withheld on June 27, 2026

Key Terms

restricted stock units, tax withholding obligations, withheld by and surrendered to the Issuer

3 terms

restricted stock units financial

"in connection with the settlement and release of the restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"to cover tax withholding obligations in connection with the settlement"

withheld by and surrendered to the Issuer financial

"Represents shares withheld by and surrendered to the Issuer to satisfy"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock transactions did Rani Therapeutics (RANI) report for Alireza Javadi?

Rani Therapeutics reported that Chief Technical Officer Alireza Javadi sold 386 shares of Class A Common Stock and had 309 shares withheld. Both transactions related to tax withholding on restricted stock unit settlements and were reported late due to administrative oversight.

How many RANI shares did Alireza Javadi sell, and at what price?

Alireza Javadi sold 386 shares of Rani Therapeutics Class A Common Stock at $0.78 per share on March 27, 2026. The sale was made to cover tax withholding obligations in connection with the settlement and release of restricted stock units.

What was the purpose of the 309 RANI shares withheld for Alireza Javadi?

The 309 shares withheld on June 27, 2026 were surrendered to the issuer to satisfy tax withholding obligations. This withholding occurred in connection with the settlement and release of restricted stock units granted to Chief Technical Officer Alireza Javadi.

Were Alireza Javadi’s Form 4 transactions in RANI stock reported on time?

Both reported transactions for Alireza Javadi were filed late due to inadvertent administrative oversight. A footnote states that each transaction is being reported late, indicating a timing issue in the reporting rather than a change in the transaction terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/21/2026 - 07:24 PM Accepted by SEC EDGAR 07/21/2026 - 07:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Javadi Alireza

(Last) (First) (Middle)

C/O RANI THERAPEUTICS LLC

2051 RINGWOOD AVE

(Street)

SAN JOSE CALIFORNIA 95131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rani Therapeutics Holdings, Inc. [ RANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/27/2026(1)		S(2)		386	D	$0.78	9,689	D
Class A Common Stock	06/27/2026(1)		F(3)		309	D	$0.74	9,380	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction is being reported late due to inadvertent administrative oversight.

2. Represents the sale of shares to cover tax withholding obligations in connection with the settlement and release of the restricted stock units.

3. Represents shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations in connection with the settlement and release of the restricted stock units.

	/s/ Carlos Perez, Attorney-in-Fact	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)